Agilon Health, Inc.

NYSE:AGL

Medical - Care Facilities

Healthcare
$90.53 +2.16%

+$2.26 today

Market cap
$1.52B
Beta
3.04
P/E (TTM)
-4.8
EPS (TTM)
-$22.50
52W Low $7.48High $118.25

Volume 0.79M

Average 0.41M

AGL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Agilon Health, Inc.NYSE: AGL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $6.79M fell 1.3% year over year, behind the +11.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at +27.6% a year.

Context

  • Depreciation & amortization amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.3% toward the trailing-twelve-month pace of +11.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.79M-2.6% QoQ
Last fiscal yearDec 2025
$28.59M+16.9% YoY
LTMMar 2026
$28.51M+11.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.3%——
1 year+16.9%——
3-year CAGR+27.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
28.59M USD
Year-over-year change
+16.9%
4-year CAGR
+18.2%

Depreciation & Amortization vs competitors

How AGL compares with its peers on the latest reported figures

  • AGL's LTM Mar 2026 depreciation & amortization of $28.51M is the 2nd largest of the 10 companies compared; the peer median is $2.17M.
  • Its year-over-year change of +11.8% is the 6th highest of 10, against a peer median of +13.0%.
  • Depreciation & amortization amounts to 0.5% of revenue for AGL, versus a peer median of 12.3%.
AGL Competitors Peer median
Depreciation & Amortization for AGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHDefinitive Healthcare Corp.LTM Mar 2026$55.54M +5.2%-0.5%23.3%
AGLAgilon Health, Inc.LTM Mar 2026$28.51M +11.8%+27.6%0.5%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$9.98M +13.0%+19.6%12.3%
SLPSimulations Plus, Inc.LTM Feb 2026$6.47M -19.3%+32.0%8.0%
DBVTDBV Technologies S.A.LTM Mar 2026$3.14M +14181.8%-37.6%—
ANNXAnnexon, Inc.LTM Mar 2026$2.17M +0.9%+0.9%—
NAKANakamoto Inc.LTM Mar 2026$1.34M +611.6%+25.6%34.2%
ENGNenGene Holdings Inc.LTM Apr 2026$670K +79.6%+28.8%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K +176.0%——
MCTACharming Medical Limited Class A Ordinary SharesFY2024$263.45K -32.7%—4.2%
Peer median (excluding AGL) $2.17M+13.0%+19.6%12.3%

Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(406.79M)(106.86M)(262.8M)(260.1M)(391.35M)
Depreciation & Amortization14.67M13.77M20.16M24.46M28.59M
Deferred Income Tax(3.23M)532K000
Stock-Based Compensation292.39M28.38M69.33M50.66M49.12M
Change in Working Capital(55.03M)(59.44M)(10.07M)130.59M189.47M
Accounts Receivables(149.04M)(204.17M)0(74.58M)344.59M
Inventory149.04M0000
Accounts Payables95.7M173.45M473.61M198.58M(87.48M)
Other Working Capital(150.72M)(28.72M)(483.68M)6.59M(67.64M)
Other Non-Cash Items9.82M(7.19M)27.18M(3.39M)18.4M
Operating Cash Flow(148.16M)(130.81M)(156.2M)(57.78M)(105.76M)
Capital Expenditures(13.43M)(32.66M)(30.82M)(13.25M)(13.24M)
Acquisitions (Net)(1.34M)500K(43.06M)00
Purchases of Investments(7.1M)(458.27M)(114.66M)(12.01M)(60.15M)
Sales of Investments7.1M52.55M164.04M206.92M193.87M
Other Investing Activities(75.74M)(23.75M)(34.51M)(41.77M)(31.87M)
Investing Cash Flow(90.51M)(444.39M)(44.02M)139.89M88.61M
Debt Repayment(19.9M)(5M)(5M)(3.75M)0
Common Stock Issued1.19B33.06M11.87M1.17M0
Common Stock Repurchased00(200M)0(2.99M)
Dividends Paid00000
Other Financing Activities(14.74M)011.87M00
Financing Cash Flow1.15B28.06M(193.13M)(2.58M)(2.99M)
Effect of Forex Changes00000
Net Change in Cash915.73M(547.14M)(393.35M)79.53M(20.15M)
Free Cash Flow(161.59M)(163.47M)(187.01M)(71.03M)(119.01M)

Agilon Health, Inc.

NYSE:AGL

Intrinsic Alpha fair value

Locked

Current Price

$90.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.